Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors
Autore:
Nordeng, H; Lindemann, R; Perminov, KV; Reikvam, A;
Indirizzi:
Ulleval Univ Hosp, Dept Pharmacotherapeut, N-0407 Oslo, Norway Ulleval Univ Hosp Oslo Norway N-0407 rmacotherapeut, N-0407 Oslo, Norway Ulleval Univ Hosp, Neonatal Intens Care Unit, Oslo, Norway Ulleval Univ Hosp Oslo Norway , Neonatal Intens Care Unit, Oslo, Norway Ulleval Univ Hosp, Dept Paediat, Oslo, Norway Ulleval Univ Hosp Oslo Norway val Univ Hosp, Dept Paediat, Oslo, Norway Cent Hosp Akershus, Dept Paediat, Neonatal Intens Care Unit, Nordbyhagen, Norway Cent Hosp Akershus Nordbyhagen Norway ns Care Unit, Nordbyhagen, Norway
Titolo Testata:
ACTA PAEDIATRICA
fascicolo: 3, volume: 90, anno: 2001,
pagine: 288 - 291
SICI:
0803-5253(200103)90:3<288:NWSAIU>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROZAC TOXICITY; FLUOXETINE;
Keywords:
antidepressants; in utero exposure; neonatal withdrawal syndrome; selective serotonin reuptake inhibitors; SSRI;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
12
Recensione:
Indirizzi per estratti:
Indirizzo: Nordeng, H Ulleval Univ Hosp, Dept Pharmacotherapeut, N-0407 Oslo, Norway Ulleval Univ Hosp Oslo Norway N-0407 eut, N-0407 Oslo, Norway
Citazione:
H. Nordeng et al., "Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors", ACT PAEDIAT, 90(3), 2001, pp. 288-291

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are a new group of antidepressants used in mild to moderate cases of depression. In studies evaluating the safety of SSRIs during pregnancy, no increase in major anomalies has been reported. This might have led to increasing off-label prescription of SSRIs to pregnant women. Neonatal withdrawal syndrome commonly occurs in infants exposed during the third trimester to drugs known to cause addiction. We report five cases of neonatal withdrawal syndrome after third trimesterin utero SSRI exposure. In three cases the mother used paroxetine in dosesfrom 10 to 40 mg, one mother used citalopram 30 mg, and one mother fluoxetine 20 mg. Withdrawal symptoms occurred within few days after birth and lasted up to one month after birth. Four of the infants needed treatment with chlorpromazine. Symptoms were irritability, constant crying, shivering. increased tonus, eating and sleeping difficulties and convulsions. Conclusion: Neonatal withdrawal syndrome can occur after third trimester in utero SSRI exposure. Further research should focus on whether it is safe to use SSRIs during the last trimester. All neonates exposed to SSRIs during the last trimester should be followed-up closely for withdrawal symptoms after birth.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 22:20:11